Chu Ming-Qiang, Zhang Ting-Juan, Feng Yuan, Shao Xun, Ji Yong-Hui, Qian Jun, Zhou Jing-Dong
Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Institute of Hematology, Jiangsu University, Zhenjiang, Jiangsu, China.
Front Immunol. 2025 Mar 31;16:1566035. doi: 10.3389/fimmu.2025.1566035. eCollection 2025.
Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with and rearrangements (DLBCL/HGBL-/) represents a distinct entity of mature aggressive B-cell lymphoma, constituting a substantial gap in the clinical management of DLBCL. Conventional R-CHOP-like chemoimmunotherapy regimens have demonstrated limited efficacy in DLBCL/HGBL-/, and the clinical outcome remains poor, with a median overall survival of less than 2 years, and even shorter in cases transformed from indolent lymphoma. We reported a 66-year-old female was firstly diagnosed with follicular lymphoma, but presented with disease progression to DLBCL/HGBL-/ during the treatment with BR regimen. Moreover, the patient was also primary refractory to Pola-R-CHP. The patient achieved partial response following treatment with the CD20×CD3 bispecific antibody glofitamab and maintained long-term remission. Although only one successful case is presented, glofitamab could be considered as salvage therapy for transformed relapsed/refractory DLBCL/HGBL-/.
伴有 和 重排的弥漫性大B细胞淋巴瘤/高级别B细胞淋巴瘤（DLBCL/HGBL-/ ）是成熟侵袭性B细胞淋巴瘤的一个独特实体，在DLBCL的临床管理中存在很大差距。传统的类似R-CHOP的化疗免疫治疗方案在DLBCL/HGBL-/ 中疗效有限，临床结局仍然很差，中位总生存期不到2年，从惰性淋巴瘤转化而来的病例生存期甚至更短。我们报告了一名66岁女性，最初被诊断为滤泡性淋巴瘤，但在接受BR方案治疗期间病情进展为DLBCL/HGBL-/ 。此外，该患者对Pola-R-CHP也原发难治。患者接受CD20×CD3双特异性抗体glofitamab治疗后获得部分缓解并维持长期缓解。虽然仅展示了一例成功病例，但glofitamab可被视为转化型复发/难治性DLBCL/HGBL-/ 的挽救治疗方法。
